PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
907.47%
Some net income increase while VET is negative at -0.17%. John Neff would see a short-term edge over the struggling competitor.
19.00%
Some D&A expansion while VET is negative at -0.71%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
63.96%
Well above VET's 83.26% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-123.68%
Both cut yoy SBC, with VET at -19.20%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
30.25%
Less working capital growth vs. VET's 165.19%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.25%
Lower 'other working capital' growth vs. VET's 165.19%. David Dodd would see fewer unexpected short-term demands on cash.
-196.00%
Both negative yoy, with VET at -78.94%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-9.26%
Negative yoy CFO while VET is 57.10%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-6.79%
Both yoy lines negative, with VET at -70.93%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
740.95%
Acquisition spending well above VET's 198.12%. Michael Burry would suspect heavier integration risk or short-term free cash flow drain vs. competitor.
1064.52%
Purchases growth of 1064.52% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-79.82%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
37.16%
Less 'other investing' outflow yoy vs. VET's 202.20%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
355.54%
Investing outflow well above VET's 38.45%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
92.80%
Debt repayment similar to VET's 99.37%. Walter Schloss sees parallel liability management or similar free cash flow availability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.